Precision medicine has enabled us to deliver customized healthcare by leveraging the interplay between molecul...
According to CareEdge Ratings, India’s orthopaedic and cardiac implant sector, including exports, which ...
Leveraging its strength in digital health innovation, Mumbai-based startup Qure.ai has launched a ...
25 Transformative Years of BIOSIMILARS
2025 marks 25 years since India first ventured into the biosimilar space. Over the past quarter century, the country has consistently solidified its position as a global leader in biosimilar approvals, with 135 approvals till January 2025. Initially focused on simpler biologics, the field now includes developing and approving complex monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), a diversified therapeutic focus, and a growing number of innovative players entering the field. As the industry celebrates this silver jubilee, we reflect on the journey that has not only transformed India's biotechnology sector but has also played a pivotal role in making life saving treatments more accessible and affordable worldwide.
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book